Navigation Links
Breakthrough in drug trial offers hope for heart attack patients
Date:9/13/2010

New findings from a major drug trial have brought experts a step closer to developing a drug which could prevent thousands of British deaths from heart attacks.

Dr Robert Storey, Reader at the University of Sheffield and Consultant Cardiologist at Sheffield Teaching Hospitals, was the UK lead for international trials of a new drug, ticagrelor, which have been taking place over the last six years.

The new findings from one of these studies, the ONSET/OFFSET study, revealed that the platelet function in patients taking ticagrelor recovered much quicker after the drug is stopped, compared to the current gold standard drug, clopidogrel. This study also confirmed that breathlessness occurs as a side effect of ticagrelor but this is not associated with any harmful effects on lung or heart function.

The findings also include a new analysis of a previous trial looking at ticagrelor. This new examination of the PLATO trial, which was completed last year, shows that ticagrelor prevents 1 in 5 deaths after a heart attack, and patients who develop the adverse effect of breathlessness with ticagrelor still benefit from a lower risk of death compared to patients treated with clopidogrel for one year following a heart attack.

Dr Storey presented these latest results at the European Society of Cardiology (ESC) Congress 2010 on 29 August 2010 and was also involved in a 10,000 patient genetic substudy of the PLATO trial that was presented at the same time and published in The Lancet. This confirmed that patients treated with clopidogrel, who have a genetic variant that reduces the effect of this drug have a slightly higher risk following heart attack but ticagrelor is not affected by this variant and is still more effective than clopidogrel, regardless of a patient's genetic make-up.

Dr Storey has been involved with the development of the new drug, ticagrelor, for the past 12 years. 90 patients from Sheffield, with acute coronary syndrome, were recruited for the PLATO trial, which involved over 18,000 cardiac patients worldwide.

The latest findings come days before World Heart Day (26 September 2010) which celebrates progress in heart health. The study has previously shown for every 1,000 patients treated for one year with ticagrelor instead of clopidogrel, there would be 14 fewer deaths or 11 fewer heart attacks without an increase in bleeding problems.

Dr Storey said: "The latest results on ticagrelor reinforce the positive data from the PLATO trial and suggest that ticagrelor has the potential to improve the quality of care and save many lives in the year following a heart attack, regardless of adverse effects or genetic differences in the response to clopidogrel."


'/>"/>

Contact: Lauren Anderson
l.h.anderson@sheffield.ac.uk
01-142-221-046
University of Sheffield
Source:Eurekalert

Related medicine news :

1. Novel nanotechnology collaboration leads to breakthrough in cancer research
2. Breakthrough news involving migraine
3. In breakthrough, nerve connections are regenerated after spinal cord injury
4. A breakthrough in tuberculosis research
5. TGen partner, PBS-Bio, makes first breakthrough drug analysis
6. Research: Major breakthrough will revolutionize the screening and treatment of genetic diseases
7. Breakthrough In Liposuction Comes To New York's Capital District
8. Hair Loss Research Study Reveals Important Breakthrough in the Treatment of Male Pattern Baldness
9. Patients at high risk of recurrences of heart disease: Breakthrough in prevention
10. John Theurer Cancer Center offers breakthrough radiation measurement technology
11. Genome breakthrough allows scientists to identify and profile tumor cells from very small samples
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... ... May 04, 2016 , ... World Patent Marketing , ... a sports invention that aids in the improvement of the grip and swing ... $9 billion," says Scott Cooper, CEO and Creative Director of World Patent Marketing. ...
(Date:5/4/2016)... Calif. (PRWEB) , ... May 04, 2016 , ... ... for children has donated 100 of its innovative kicking trainers to St. Jude ... , The SOCKIT is a durable, lightweight rubber band designed to teach children ...
(Date:5/4/2016)... ... May 04, 2016 , ... Cirius, a ... for its innovative Secure Messaging platform, which includes secure, private messaging, large file ... extends Cirius’s portfolio of patents around innovative features for securing, tracking, and controlling ...
(Date:5/4/2016)... (PRWEB) , ... May 04, 2016 , ... ... Technology & Business Conference. The conference opened on Tuesday with Frank Luntz, sharing ... on NCPDP’s PDMP Solution provided a deep dive on NCPDP’s model solution to ...
(Date:5/4/2016)... ... May 04, 2016 , ... ... disorder management, today announced it has secured $9 million in Series A funding ... investors. The investment will be used by Somnoware to further fulfill its mission ...
Breaking Medicine News(10 mins):
(Date:5/4/2016)... JERUSALEM , May 4, 2016 ... University of Jerusalem announced today that it had ... BioTheryX, Inc. , developer of novel protein degradation ... the development and commercialization of drug candidates representing first-in-class ... the license were not disclosed. The novel ...
(Date:5/4/2016)... May 4, 2016 ... the  "Global Multiple Myeloma Market and Competitive ... offering.       (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ... and Competitive Landscape Highlights 2016, provides comprehensive ... Myeloma epidemiology, Multiple Myeloma market valuations and ...
(Date:5/4/2016)... 2016 Research and ... Actinic Keratosis Market and Competitive Landscape Highlights ...      (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ) ... Landscape Highlights 2016, provides comprehensive insights into ... Actinic Keratosis market valuations and forecast, Actinic ...
Breaking Medicine Technology: